Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

NAD+ Oral Supplement Pilot Intervention in Adult Females

NCTNCT06579209 (opens ClinicalTrials.gov in a new tab)Other id2087241-4Other idP20GM103430
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Not applicable
Enrollment
53 participants (actual)
Sponsor
University of Rhode Island · Other
Design
Randomized · Double masking
Countries
1 country

United States

Start
1 Dec 2024
Primary completion
20 Feb 2026
Completion
20 Feb 2026
First posted
30 Aug 2024
Last update posted
12 Mar 2026
Conditions
Cognitive Change · Inflammation · Neurodegenerative Diseases

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2024202520262027
  1. N/A

    NAD+ Oral Supplement Pilot Intervention in Adult Females

    NCT06579209

    1 Dec 2024 to 20 Feb 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are: Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ. Participants will: Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Interventions

  • TreatmentDietary supplement
  • PlaceboOther

Arms3

  • No intervention

    Pre-testing prior to intervention

    Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.

  • No intervention

    Post-testing after intervention

    After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.

  • Experimental

    Intervention

    For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.

Primary outcomes3

Outcomes the sponsor listed as primary.

  1. Neurocognition

    Time frame · four weeks

    Registry description

    NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics

  2. Neurodegenerative disease panel

    Time frame · four weeks

    Registry description

    BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1

  3. Markers of systemic inflammation

    Time frame · four weeks

    Registry description

    GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
Female
Age
from 40 Years up to 80 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Identify as Female * Have a BMI of 18.5 or above * Must be able to swallow tablets Exclusion Criteria: * Those who are pregnant, breastfeeding, or taking hormone medication

PepBank is a research reference. Talk to a doctor before you use any peptide.